Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors.

Autor: Shields JD; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Aquila BM; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Emmons D; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Finlay MRV; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Gangl ET; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Gu C; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Mlynarski SN; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Petersen J; Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Pop-Damkov P; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Sha L; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Simpson I; Early Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, U.K., Tavakoli S; Discovery Sciences, R&D, AstraZeneca, Pepparedsleden 1, SE-431 83 Mölndal, Sweden., Tentarelli S; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Wang H; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Ye Q; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States., Zheng X; Early Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.

Publikováno v: Journal of medicinal chemistry [J Med Chem] 2024 Nov 14. Date of Electronic Publication: 2024 Nov 14.

A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer.

Autor: Alonso-Gordoa T; Hospital Universitario Ramón y Cajal, Madrid, Spain. Electronic address: talonso@salud.madrid.org., Goodman M; Atrium Health Wake Forest Baptist, Winston-Salem, USA., Vulsteke C; Integrated Cancer Center, Maria Middelares General Hospital, Ghent; Center for Oncological Research, University of Antwerp, Antwerp, Belgium., Roubaud G; Institut Bergonié, Bordeaux, France., Zhang J; H. Lee Moffitt Cancer Center & Research Institute, Tampa., Parikh M; Hematology/Oncology Clinic, UC Davis Comprehensive Cancer Center, Sacramento, USA., Piulats JM; Catalan Institute of Oncology, Barcelona, Spain., Azaro A; Oncology R&D, AstraZeneca, Cambridge., James GD; Medical Statistics Consultancy Ltd, London, UK., Cavazzina R; Oncology R&D, AstraZeneca, Cambridge., Gangl ET; BioPharma R&D, AstraZeneca, Boston., Thompson J; Oncology R&D, AstraZeneca, Cambridge., Pouliot G; Oncology R&D, AstraZeneca, Waltham., Kumar R; Oncology R&D, AstraZeneca, Gaithersburg., Sweeney C; Dana-Farber Cancer Institute, Boston, USA.

Publikováno v: ESMO open [ESMO Open] 2024 Jun; Vol. 9 (6), pp. 103446. Date of Electronic Publication: 2024 Jun 04.

The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Autor: Lawson M; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Cureton N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Ros S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Cheraghchi-Bashi A; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Urosevic J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., D'Arcy S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Delpuech O; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., DuPont M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Fisher DI; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Gangl ET; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Lewis H; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Trueman D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Wali N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Williamson SC; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Moss J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Montaudon E; Institut Curie, Paris, France., Derrien H; Institut Curie, Paris, France., Marangoni E; Institut Curie, Paris, France., Miragaia RJ; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Gagrica S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Morentin-Gutierrez P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Moss TA; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Maglennon G; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Sutton D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Polanski R; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Rosen A; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts., Cairns J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Zhang P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Critchlow SE; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Scott JS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Lindemann JPO; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Barry ST; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom., Morrow CJ; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom., Carnevalli LS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2023 Dec 01; Vol. 83 (23), pp. 3989-4004.